How much can we learn from long-term extension trials in multiple sclerosis?
Author:
- 26 September 2006
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 67 (6) , 930-931
Abstract
No one has solved the riddle of how best to conduct long-term, blinded MS trials and, consequently, definitive evidence that treatment protects against progression in disability remains elusive. The report by Kappos et al.14 attempts to make the most of the imperfect world of extension trials, a methodology that has been used by others to provide similar insight on the value of prolonged treatment with glatiramer acetate.15Keywords
This publication has 15 references indexed in Scilit:
- Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MSNeurology, 2006
- A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006
- Natalizumab plus Interferon Beta-1a for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006
- Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year dataActa Neurologica Scandinavica, 2005
- A Controlled Trial of Natalizumab for Relapsing Multiple SclerosisNew England Journal of Medicine, 2003
- Randomized, comparative study of interferon β-1a treatment regimens in MSNeurology, 2002
- Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple SclerosisNew England Journal of Medicine, 2000
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995
- Interferon beta‐lb in the treatment of multiple sclerosisNeurology, 1995
- Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosisNeurology, 1993